Evaluation and treatment of depression in dementia
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252053Keywords:
Antidepressant, Apathy, Depression, DementiaAbstract
Depression in later life is common with depressive symptoms present in 15% of all older adults and is often associated with coexisting chronic medical conditions, cognitive dysfunction or both. Although the depressive in later life conduction frequently manifests subthreshold symptoms such as not to satisfy the diagnostic criteria of DSM V, depression in the course of dementia should not be underestimated. The clinical features of depression associated with dementia vary from dysthymia-type psychopathological conditions to major depressive forms. Scientific evidence leans towards depression, not only as a comorbidity occurring in the various forms of dementia but as a significant contributor to the dementia etiopathogenesis. Depression in later life can be a prodrome, risk factor, comorbidity or consequence of mild cognitive impairment and dementia. In clinical practice in patients with dementia it is necessary to distinguish depression from apathy which is very frequent and overlaps with depression. Treatment of the psychological behavioural symptoms of dementia (BPDS), including depression, should initially be addressed non-pharmacologically with integrated management, as indicated by several guidelines as a first-line treatment approach except in emergency situations or severity.
Metrics
References
Hermida AP, McDonald WM, Steenland K, Levey A. The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link. Expert Rev Neurotherap. 2012;12(11):1339-50. DOI: https://doi.org/10.1586/ern.12.127
Cristina D. The pharmacological treatment of behavioral alterations in the course of dementia. J Geriat Mental Health. 2022;9(1):60-2.
Grossberg GT, Tong G, Burke AD, Tariot PN. Present algorithms and future treatments for Alzheimer’s disease. J Alzheimer’s Dis. 2019;67(4):1157-71. DOI: https://doi.org/10.3233/JAD-180903
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Previsione del carico globale del morbo di Alzheimer. Demenza di Alzheimer. 2007;3:186–91. DOI: https://doi.org/10.1016/j.jalz.2007.04.381
Cristina D. The pharmacological treatment of behavioral alterations in the course of dementia. J Ger Mental Health. 2022;9(1):60-2. DOI: https://doi.org/10.4103/jgmh.jgmh_18_22
Osvaldo P. Almeida Prevention of depression in older age Maturitas. 2014;79(2);136-41. DOI: https://doi.org/10.1016/j.maturitas.2014.03.005
Smith KR. Methylphenidate use in geriatric depression: A systematic review Int Geriatric Psychiatry. 2021;36(9):1304-12. DOI: https://doi.org/10.1002/gps.5536
Kaplan HI. Synopsis of psychiatry behavioral sciences. Clinical Psychiatry. 1998.
Yudofsky SC, Hales RE, Roberts LW. Manuale di psichiatria: American Psychiatric Publishing. Edra Masson. 2015.
Miodek A, Szemraj P, Kocur J, Ryś A. Masked depression--history and present days. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. 2007;23(133):78-80.
Yesavage JA. Depression in the elderly: How to recognize masked symptoms and choose appropriate therapy. Postgraduate Med. 1992;91(1):255-61. DOI: https://doi.org/10.1080/00325481.1992.11701181
Williams R. Perché abbiamo bisogno di un'anima psicodinamica: il problema del rapporto tra psicoanalisi e neuroscienze nel PDM-2. Giornale Italiano di Psicologia. 2018;45(4):915-22.
Bruce ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry. 2002;52:175–84. DOI: https://doi.org/10.1016/S0006-3223(02)01410-5
Sözeri-Varma G. Depression in the elderly: clinical features and risk factors. Aging and Dis. 2012;3(6):465.
Morimoto SS, Kanellopoulos D, Manning KJ, Alexopoulos GS. Diagnosis and treatment of depression and cognitive impairment in late life. Ann New York Acad Sci. 2015;1345(1):36-46. DOI: https://doi.org/10.1111/nyas.12669
Invernizzi G, Bressi C. Manuale di psichiatria e psicologia clinica. Mc Graw Hill. 2012.
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database System Rev. 2018;5:1857. DOI: https://doi.org/10.1002/14651858.CD012197.pub2
Ishii S, Weintraub N, Mervis JR. Apathy: a common psychiatric syndrome in the elderly. J Am Med Direc Assoc. 2009;10(6):381-93. DOI: https://doi.org/10.1016/j.jamda.2009.03.007
Benoit M, Andrieu S, Lechowski L, Gillette‐Guyonnet S, Robert PH, Vellas B. Apathy and depression in Alzheimer's disease are associated with functional deficit and psychotropic prescription. Int J Geriat Psych. 2008;23(4):409-14. DOI: https://doi.org/10.1002/gps.1895
Ducharme S, Price BH, Dickerson BC. Apathy: a neurocircuitry model based on frontotemporal dementia. J Neurol, Neurosurg Psych. 2018;89(4):389-96. DOI: https://doi.org/10.1136/jnnp-2017-316277
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308. DOI: https://doi.org/10.1212/WNL.44.12.2308
Azhar L, Kusumo RW, Marotta G, Lanctôt KL, Herrmann N. Pharmacological management of apathy in dementia. CNS Drugs. 2022;36(2):143-65. DOI: https://doi.org/10.1007/s40263-021-00883-0
Eikelboom WS, Pan M, Ossenkoppele R, Coesmans M, Gatchel JR, Ismail Z, et al. Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis. Alzheimer's Res Ther. 2022;14(1):48. DOI: https://doi.org/10.1186/s13195-022-00991-z
Ford AH, Almeida OP. Management of depression in patients with dementia: is pharmacological treatment justified. Drugs Aging. 2017;34:89-95. DOI: https://doi.org/10.1007/s40266-016-0434-6
O'Dwyer ST, Moyle W, Zimmer-Gembeck M, De Leo D. Suicidal ideation in family carers of people with dementia. Aging Mental Health. 2016;20(2):222-30. DOI: https://doi.org/10.1080/13607863.2015.1063109
Angelini C, Battistin L. Neurologia clinica. Società Editrice Esculapio. 2022.
Bastida JD, Pomés NP, Font SJ, Eickhoff AF. La depresión: un predictor de demencia. Revista espanola de geriatria y gerontologia. 2016;51(2):112-8. DOI: https://doi.org/10.1016/j.regg.2015.10.008
Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. John Wiley & Sons. 2025.
Mukhopadhyay S, Banerjee D. The complex conundrum of geriatric depression and dementias: Revisiting the clinical ambiguity. J Geriat Mental Health. 2021;8(2):93-106. DOI: https://doi.org/10.4103/jgmh.jgmh_21_21
Perri R, Turchetta CS, Caruso G, Fadda L, Caltagirone C, Carlesimo GA. Neuropsychological correlates of cognitive, emotional-affective and auto-activation apathy in Alzheimer's disease. Neuropsychologia. 2018;118:12-21. DOI: https://doi.org/10.1016/j.neuropsychologia.2018.01.039
Brodaty H, Connors MH. Pseudodementia, pseudo‐pseudodementia, and pseudodepression. Alzheimer's & Dementia: Diagnosis, Assessment Disease Monitoring. 2020;12(1):12027. DOI: https://doi.org/10.1002/dad2.12027
Tetsuka S. Depression and dementia in older adults: a neuropsychological review. Aging Disease. 2021;12(8):1920. DOI: https://doi.org/10.14336/AD.2021.0526
Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104-20. DOI: https://doi.org/10.1038/s41386-019-0478-5
Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of minor and major depression in Alzheimer’s disease. American J Psychiat. 2005;162(11):2086-93. DOI: https://doi.org/10.1176/appi.ajp.162.11.2086
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73. DOI: https://doi.org/10.3389/fneur.2012.00073
Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence Lancet Neurol. 2011;10(9):819-28. DOI: https://doi.org/10.1016/S1474-4422(11)70072-2
Blazer DG, Hybels CF. What symptoms of depression predict mortality in community-dwelling elders. J Am Geriatr Soc. 2011;52:2052-6. DOI: https://doi.org/10.1111/j.1532-5415.2004.52564.x
Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression: a central role for the serotonin transporter. Pharmacology & therapeutics. 2015;147:1-1. DOI: https://doi.org/10.1016/j.pharmthera.2014.10.002
Cui Y, Jin X, Choi JY, Kim BG. Modeling subcortical ischemic white matter injury in rodents: unmet need for a breakthrough in translational research. Neu Regen Res. 2021;16(4):638-42. DOI: https://doi.org/10.4103/1673-5374.295313
Jeon SW, Kim YK. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. J Inflamm Res. 2018;3:179-92. DOI: https://doi.org/10.2147/JIR.S141033
Thomas AJ, Perry R, Barber R, Kalaria RN, O'Brien JT. Pathologies and pathological mechanisms for white matter hyperintensities in depression. Ann NY Acad Sci. 2002;977:333–9. DOI: https://doi.org/10.1111/j.1749-6632.2002.tb04835.x
Stahl SM, Gessa GL, Muntner N, Pani L. Psicofarmacologia essenziale: basi neuroscientifiche e applicazioni pratiche. Centro Scientifico Editore. 2002.
Huang EJ. TRK receptors: roles in neuronal signal transduction. Ann Rev Biochem. 2003;72:609–42. DOI: https://doi.org/10.1146/annurev.biochem.72.121801.161629
Duman SR. Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238–49. DOI: https://doi.org/10.1038/nm.4050
Lozupone M, La Montagna M, D’Urso F, Piccininni C, Rinaldi A, Beghi M et al. The challenge of antidepressant therapeutics in Alzheimer’s disease. Rev New Drug Targ Age-Rel Disord. 2020:267-81. DOI: https://doi.org/10.1007/978-3-030-42667-5_10
Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psych. 2012;69(5):493–8. DOI: https://doi.org/10.1001/archgenpsychiatry.2011.1481
Kumar A, Kepe V, Barrio JR, Siddarth P, Manoukian V, Elderkin-Thompson V, et al. Protein binding in patients with late-life depression. Arch Gen Psych. 2011;68:1143-50. DOI: https://doi.org/10.1001/archgenpsychiatry.2011.122
Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psych. 1988;23(3):271-84. DOI: https://doi.org/10.1016/0006-3223(88)90038-8
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res. 1982;17(1):37-49. DOI: https://doi.org/10.1016/0022-3956(82)90033-4
Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck depression Inventory‐II (BDI‐II), center for epidemiologic studies depression scale (CES‐D), geriatric depression scale (GDS), hospital anxiety and depression scale (HADS), and patient health Questionnaire‐9 (PHQ‐9). Arth Care Res. 2011;63(11):454-66. DOI: https://doi.org/10.1002/acr.20556
Wilkins CH, Mathews J, Sheline YI. Late life depression with cognitive impairment: evaluation and treatment. Clin Interven Aging. 2009;2:51-7. DOI: https://doi.org/10.2147/CIA.S3154
Geniušas S. The pathos of time: Chronic pain and temporality. Dialogue and Universalism. 2015(3):25-38. DOI: https://doi.org/10.5840/du201525365
Baruch N, Burgess J. Treatment for depression comorbid with dementia. Evid Based Ment Health. 2019;22(4):167-71. DOI: https://doi.org/10.1136/ebmental-2019-300113
Brodaty H, Arasaratham C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symtons of dementia. Am J Psychiatry. 2012;169:946-53. DOI: https://doi.org/10.1176/appi.ajp.2012.11101529
Preuss UW, Wong JWM. Treatment of Behavioral and psychological symtoms of dementia: a systematic review. Psychiatr Pol. 201650(4):679-715. DOI: https://doi.org/10.12740/PP/64477
Pittenger C, Duman RS. Stress, depression and neuroplasticity: a convergence of mechanisms. Psychopharmacology. 2008;33:88-109. DOI: https://doi.org/10.1038/sj.npp.1301574
Stahl SM. Stahl's Illustrated Antidepressants. Cambridge University Press. 2009. DOI: https://doi.org/10.1017/9781139194457
Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia Cochrane Database Syst Rev. 2011;16(2):8191. DOI: https://doi.org/10.1002/14651858.CD008191.pub2
Qasim HS, Simpson MD. A narrative review of studies comparing efficacy and safety of citalopram with atypical antipsychotics for agitation in behavioral and psychological symptoms of dementia. Review Pharm. 2022;10(3):61. DOI: https://doi.org/10.3390/pharmacy10030061
Lopez‐Pousa S. Trazodone for Alzheimer’s disease: a naturalistic follow‐up study. Arch Gerontol Geriatr. 2008;47:207–15. DOI: https://doi.org/10.1016/j.archger.2007.07.010
Downloads
Published
How to Cite
Issue
Section
